Piramal Pharma Limited

NSE: PPLPHARMA · Pharmaceuticals · sector

₹195.17NSE close 2026-10-26

Key numbers

Market cap₹25,906 cr

Price₹195.17

52w high / low₹232 / ₹132

P/E–Sector median 27.9x

P/B3.2xSector median 2.9x

Book value₹61.5

Dividend yield0.07%Sector median 0.48%

ROE-3.9%Sector median 11.7%

ROCE1.3%Sector median 12.3%

OPM8.6%Sector median 14.0%

Debt / equity0.67xSector median 0.16x

EV/EBITDA37.9xSector median 18.6x

Interest cover0.5x

Current ratio1.51x

Sales growth 3y+7.8%Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG–

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1,355 cr vs borrowings ₹5,495 cr (FY26): borrowings are higher by ₹4,140 cr.
Operating profit covered interest 0.5x in the last 12 months.
Operating cash flow was below net profit in 0 of the last 4 years.
Net loss in 5 of the last 8 quarters.
Revenue was higher than a year earlier in 1 of the last 4 quarters.
Dividend paid in 2 of the last 4 financial years.
Price ₹195.17 on 2026-10-26: -15.8% from the 52-week high, +47.5% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹274.15 · low ₹133.27

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	2,242	2,204	2,754	1,934	2,044	2,140	2,752	2,270
EBITDA	342	338	561	127	159	155	285	195
OPM %	15.2%	15.3%	20.4%	6.6%	7.8%	7.2%	10.3%	8.6%
Other income	61	12	42	58	66	43	46	89
Net profit	23	4	154	-82	-99	-136	-9	-69
EPS (₹)	0.17	0.03	1.16	-0.62	-0.75	-1.03	-0.07	-0.52
Revenue YoY					-8.8%	-2.9%	-0.1%	+17.4%
Profit YoY					-539.2%	-3,800.8%	-105.7%	–

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY23	FY24	FY25	FY26	TTM
Revenue	7,082	8,171	9,151	8,869	9,205
EBITDA	621	1,133	1,445	725	793
Net profit	-186	18	91	-326	-314
EPS (₹)	-1.57	0.14	0.69	-2.46	-2.37
Revenue growth		+15.4%	+12.0%	-3.1%	+0.8%
Profit growth		–	+411.4%	-457.7%	-419.8%
Dividend / share (₹)	–	–	0.11	0.14

Compounded growth	3 years	5 years	Last 12 months
Sales	+7.8%	–	+0.8%
Net profit	–	–	-419.8%
EPS	–	–	–
Share price	–	-8.4% (2y)	-3.1%

Balance sheet

₹ cr	FY23	FY24	FY25	FY26
Shareholders' equity	6,774	7,911	8,125	8,163
Borrowings	5,505	4,559	4,720	5,495
Cash & equivalents	735	627	521	1,355
Total assets	14,523	15,312	15,678	17,965
Fixed assets	3,363	3,873	4,176	4,451
Capital work in progress	853	566	489	799
Investments	42	35	44	61
Receivables	1,799	2,134	2,350	2,158
Inventory	1,681	2,176	2,313	3,064
Payables	1,193	1,538	1,534	2,479

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY23	FY24	FY25	FY26
Cash from operations	484	1,005	892	1,653
Cash from investing	-1,339	-434	-477	-826
Cash from financing	818	-422	-441	-39
Capex	965	712	664	890
Free cash flow	-481	292	228	763

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY23	FY24	FY25	FY26
ROE %	-2.8%	0.2%	1.1%	-4.0%
ROCE %	1.4%	4.6%	5.9%	0.8%
Debtor days	93	95	94	89
Inventory days	227	269	261	345
Payable days	161	190	173	279
Cash conversion cycle (days)	159	174	182	155
Working capital days	51	49	81	100

Shareholding

Holder	% (2026-09-30)
Promoters	34.80%
FIIs	13.65%
DIIs	14.44%
of which Mutual funds	12.71%
of which Insurance	1.23%
Government	0.00%
Public (non-institutions)	36.71%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	34.95%	34.95%	34.86%	34.86%	34.86%	34.86%	34.80%	34.80%

Promoter group	%
The Sri Krishna Trust (through its Trustee Mr. Ajay G Piramal and Dr. (Mrs.) Swati A. Piramal)	26.51%
V3 Designs LLP	3.23%
PRL Realtors LLP	2.99%
Piramal Welfare Trust	0.79%
Semplice Corporate Solutions Private Limited	0.67%
The Ajay G Piramal Foundation	0.33%
Mr. Anand Piramal	0.07%
Anand Piramal Trust	0.05%
Mr. Ajay G. Piramal	0.04%
Nandini Piramal Trust	0.04%
Mr. Peter DeYoung	0.03%
Ms. Nandini Ajay Piramal	0.02%
Ms. Anya Piramal DeYoung	0.01%
Master Dev Piramal DeYoung	0.01%
Dr. (Mrs.) Swati A. Piramal	0.00%

Public holders above 1%	%
Ca Alchemy Investments	17.93%
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund	5.65%
East Bridge Capital Master Fund I Ltd	2.00%
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund	1.56%
Indiahold Limited	1.30%

4,13,197 shareholders. Pledged: – of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
PPLPHARMA	₹25,906 cr	–	3.2x	-3.9%	1.3%	8.6%	+7.8%	0.07%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2025-07-16	Dividend	Dividend - Re 0.14 Per Share
2024-07-12	Dividend	Dividend - Rs 0.11 Per Share
2023-08-02	Rights	Rights 5:46 @ Premium Rs 71/-

Documents

Links go to the original files on the exchange website.

About the company

Pharmaceuticals: Manufacturing of pharmaceuticals, medicinal, chemical and botanical products


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	PPLPHARMA
BSE code	543635
ISIN	INE0DK501011
Face value	₹10.0
Incorporated	2020-03-04
Website	www.piramalpharma.com
Plants (India / abroad)	9 / 7

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.